Eleutheroside E Ameliorates Arthritis Severity in Collagen-Induced Arthritis Mice Model by Suppressing Inflammatory Cytokine Release

Inflammation

Volumn 37, Issue 5, 2014, Pages 1533-1543

  He, Chunyan ^a   Chen, Xiaohui ^a   Zhao, Chunyang ^a   Qie, Yanyan ^a   Yan, Zhaowei ^b   Zhu, Xueming ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

eleutheroside E; inflammatory cytokines; rheumatoid arthritis; treatment

Indexed keywords

ELEUTHEROSIDE E; INTERLEUKIN 6; PLANT MEDICINAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; COLLAGEN TYPE 2; CYTOKINE; GLUCOSIDE; LIGNAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE EROSION; CARTILAGE INJURY; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFLAMMATORY CELL; MALE; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BOVINE; CHEMICALLY INDUCED; DBA MOUSE; METABOLISM; SEVERITY OF ILLNESS INDEX;

ELEUTHEROCOCCUS SENTICOSUS; MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CATTLE; COLLAGEN TYPE II; CYTOKINES; GLUCOSIDES; INFLAMMATION MEDIATORS; LIGNANS; MALE; MICE; MICE, INBRED DBA; SEVERITY OF ILLNESS INDEX;

EID: 84918835297     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9880-7     Document Type: Article

References (33)

1. Weissmann, G. 2006. The pathogenesis of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 6: 12–15.
2. Feldmann, M., and S.R. Maini. 2008. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunological Reviews 223: 7–19.
3. Sack, U., R.W. Kinne, T. Marx, P. Heppt, S. Bender, and F. Emmrich. 1993. Interleukin-6 in synovial-fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatology International 13: 45–51.
4. Madhok, R., A. Crilly, J. Watson, and H.A. Capell. 1993. Serum interleukin-6 levels in rheumatoid arthritis-correlations with clinical and laboratory indexes of disease activity. Annals Rheumatic Diseases 52: 232–234.
5. Hashizume, M., and M. Mihara. 2011. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. doi:10.1155/2011/765624.
6. Palmqvist, P., E. Persson, H.H. Conaway, and U.H. Lerner. 2002. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. Journal of Immunology 169: 3353–3362.
7. Ohta, S., K. Imai, K. Yamashita, T. Matsumoto, I. Azumano, and Y. Okada. 1998. Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage. Laboratory Investigation 78: 79–87.
8. Feldmann, M., and R.N. Maini. 2001. Anti-TNFα therapy or rheumatoid arthritis: what have we learned? Annual Review Immunology 19: 163–196.
9. Dixon, W.G., and D.P. Symmons. 2007. What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortalityin rheumatoid arthritis? A review of the role of TNF alpha in cardiovascular pathophysiology. Annals of the Rheumatic Disease 66: 1132–1136.
10. Gomez-Reino, J.J., L. Carmona, V.R. Valverde, E.M. Mola, and M.D. Montero. 2003. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis and Rheumatism 48: 2122–2127.
11. Charles, P.J., R.J. Smeenk, J. De Jong, M. Feldmann, and R.N. Maini. 2000. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis and Rheumatism 43: 2383–2390.
12. Shakoor, N., M. Michalska, C.A. Harris, and J.A. Block. 2002. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579–580.
13. Nishibe, S., H. Kinoshita, H. Takeda, and G. Okano. 1990. Phenolic compounds from stem bark of Acanthopanax senticosus and their pharmacological effect in chronic swimming stressed rats. Chemical & Pharmaceutical Bulletin 38: 1763–1765.
14. Yu, C.Y., S.H. Kim, J.D. Lim, M.J. Kim, and I.M. Chung. 2003. Intraspecific relationship analysis by DNA markers and in vitro cytotoxic and antioxidant activity in Eleutherococcus senticosus. Toxicology In Vitro 17: 229–236.
15. Schmolz, M.W., F. Sacher, and B. Aicher. 2001. The synthesis of Rantes, G-CSF, IL-4, IL-5, IL-6, IL-12 and IL-13 in human whole-blood cultures is modulated by an extract from Eleutherococcus senticosus L. roots. Phytotherapy Research 15: 268–270.
16. Yan, Z.W., J.P. Liu, D. Lu, R. Narlawar, P. Groundwater, and P.Y. Li. 2013. Two new ceramides from the fruit pulp of Acanthopanax senticosus (Rupr.et Maxim) Harms. Natural Product Research. doi:10.1080/14786419/2013/856908.
17. Clague, R.B., K. Morgan, T.I. Reynolds, and H.J. Williams. 1994. The prevalence of serum IgG antibodies to type ii collagen in American patients with rheumatoid arthritis. British Journal of Rheumatology 33: 336–338.
18. Weyand, C.M. 2000. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology 39: 3–8.
19. Brand, D.D., A.H. Kang, and E.F. Rosloniec. 2003. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathology 25: 3–18.
20. Tokiwa, T., T. Yamazaki, and S. Sakurai. 2006. Anti-inflammatory effect of eleutheroside E from Acanthopanax senticosus. Foods and Food Ingredients Journal of Japan 211: 576–582.
21. Yamazaki, T., T. Matsumura, T. Tsukiyama, and T. Tokiwa. 2006. Anti-inflammatory effects of eleutheroside E from Acanthopanax senticosus. Tissue Culture Research Communications 25: 137–145.
22. Yamazaki, T., S. Shimosaka, H. Sasaki, T. Matsumura, T. Tukiyama, and T. Tokiwa. 2007. (+)-Syringaresinol-di-O-beta-D-glucoside, a phenolic compound from Acanthopanax senticosus Harms, suppresses proinflammatory mediators in SW982 human synovial sarcoma cells by inhibiting activating protein-1 and/or nuclear factor-kappaB activities. Toxicology In Vitro 21: 1530–1537.
23. Huang, L.Z., L. Wei, H.F. Zhao, B.K. Huang, K. Rahman, and L.P. Qin. 2011. The effect of eleutheroside E on behavioral alterations in murine sleep deprivation stress model. European Journal Pharmacology 658: 150–155.
24. Ahn, J., M.Y. Um, H. Lee, C.H. Jung, S.H. Heo, and T.Y. Ha. 2013. Eleutheroside E, an active component of Eleutherococcus senticosus, ameliorates insulin resistance in type 2 diabetic db/db mice. Evidence Based Complementary and Alternative Medicine. doi:10.1155/2013/934183.
25. Elliott, M.J., R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, H. Bijl, and J.N. Woody. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125–1127.
26. Elliott, M.J., R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane, H. Bijl, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105–1110.
27. Lipsky, P.E., D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, M. Weisman, P. Emery, M. Feldmann, G.R. Harriman, and R.N. Maini. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine 343: 1594–1602.
28. Maruotti, N., F.P. Cantatore, E. Crivellato, A. Vacca, and D. Ribatti. 2006. Angiogenesis in rheumatoid arthritis. Histology of Histopathology 21: 557–566.
29. Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. Journal of Experimental Medicine 187: 461–468.
30. Smolen, J.S., A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, E. Alecock, T. Woodworth, and R. Alten. 2008. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987–997.
31. Brand, D.D., K.A. Latham, and E.F. Rosloniec. 2007. Collagen-induced arthritis. Nature Protocols 2: 1269–1275.
32. Rowley, M.J., K.S. Nandakumar, and R. Holmdahl. 2008. The role of collagen antibodies in mediating arthritis. Modern Rheumatology 18: 429–441.
33. Kuhn, K.A., L. Kulik, B. Tomooka, K.J. Braschler, W.P. Arend, W.H. Robinson, and V.M. Holers. 2006. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. Journal of Clinical Investigation 116: 961–973.